Skeletal muscle defects do arise in Vav2L332A/L332A mice though [39], thereby suggesting that the use of Vav2 inhibitors could eventually lead to the loss of muscle mass and the development of a metabolic syndrome condition if administered during very long periods of time. This evidence concerns the gene VAV2 and metabolic syndrome.